Clinical Trials Logo

Filter by:
NCT ID: NCT01026857 Completed - Ulcerative Colitis Clinical Trials

Propionyl-L-Carnitine in Ulcerative Colitis

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Propionyl-L-carnitine administration may ameliorate the illness in patients affected by mild to moderate ulcerative colitis already in treatment with one of the standard treatments (corticosteroids excluded).

NCT ID: NCT01023581 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

AM7D
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.

NCT ID: NCT01020448 Completed - Prostate Cancer Clinical Trials

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Triptocare
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.

NCT ID: NCT01020123 Completed - Clinical trials for Type II Diabetes Mellitus

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

NCT ID: NCT01018173 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Start date: January 2010
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly, or weekly sc placebo, in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease. Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.

NCT ID: NCT01015287 Completed - Clinical trials for Acute Coronary Syndromes

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

ACCOAST
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).

NCT ID: NCT01013675 Completed - Influenza Vaccines Clinical Trials

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Start date: November 2009
Phase: Phase 2
Study type: Interventional

A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.

NCT ID: NCT01011322 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The participation in this clinical study will last approximately 21 weeks with a 1 week screening period and a 12 weeks treatment duration. If the study doctor finds, that the patients disease has significantly improved he/she will enter a treatment free follow-up period of 8 weeks. In total the study consists of 5 to 6 clinical visits (V1 - V6) and 1 telephone follow-up call.

NCT ID: NCT01009086 Completed - Clinical trials for Arthritis, Psoriatic

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.

NCT ID: NCT01001377 Completed - Clinical trials for Metastatic Colorectal Cancer

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Start date: February 2, 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.